Last reviewed · How we verify

Janssen-Cilag S.p.A. — Portfolio Competitive Intelligence Brief

Janssen-Cilag S.p.A. pipeline: 1 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Efavirenz (EFV) Efavirenz (EFV) marketed Non-nucleoside reverse transcriptase inhibitor (NNRTI) HIV reverse transcriptase Infectious Disease / Virology
Darunavir/Ritonavir (DRV/r) Darunavir/Ritonavir (DRV/r) phase 3 Protease inhibitor (PI) HIV protease Infectious Disease / Virology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · 1 shared drug class
  2. Centers for Disease Control and Prevention · 1 shared drug class
  3. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 shared drug class
  4. French National Agency for Research on AIDS and Viral Hepatitis · 1 shared drug class
  5. Germans Trias i Pujol Hospital · 1 shared drug class
  6. International Partnership for Microbicides, Inc. · 1 shared drug class
  7. Janssen Infectious Diseases BVBA · 1 shared drug class
  8. Johns Hopkins Bloomberg School of Public Health · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Janssen-Cilag S.p.A.:

Cite this brief

Drug Landscape (2026). Janssen-Cilag S.p.A. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/janssen-cilag-s-p-a. Accessed 2026-05-17.

Related